Exact Sciences chairman and CEO Kevin Conroy delivered the company's presentation at the 2015 Baird 2015 Healthcare Conference in New York at 9:40 a.m. ET on Wednesday, Sept. 9.
An archive of the webcast is available here: http://wsw.com/webcast/baird43/register.aspx?conf=baird43&page=exas&url=http://wsw.com/webcast/baird43/exas/index.aspx
Exact Sciences chairman and CEO Kevin Conroy delivered the company's presentation at the 2015 Baird 2015 Healthcare Conference in New York at 9:40 a.m. ET on Wednesday, Sept. 9.
An archive of the webcast is available here: http://wsw.com/webcast/baird43/register.aspx?conf=baird43&page=exas&url=http://wsw.com/webcast/baird43/exas/index.aspx
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Aridis Pharmaceuticals is a late-stage clinical development company, leading the creation of transformative, first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. The company’s lead drug candidate for acute pneumonia met all endpoints for its phase 2 clinical trial and the Company is now preparing for a phase 3 study. Its pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of viral pandemics and antimicrobial resistant (AMR) bacteria. Its anti-toxin monoclonal antibody approach is a proven Mechanism of Action and has shown efficacy as a combination therapy in reducing acute pneumonia patients time in ICU as compared to the current standard of care, which is antibiotics. In addition to its phase 3 program, ARDS also has a phase 2 asset for the treatment of Bacteria HAP/VAP LPS 011. It also recently began enrolling for a phase 2 clinical trial for the treatment of Cystic Fibrosis patients with acute pneumonia, a program funded by the Cystic Fibrosis Foundation for $7.5 million. Importantly, ARDS is also preparing to launch a Phase 1/2 clinical trial in the second half of 2021 with its novel inhalation antibody technology for emerging COVID-19 mutated variants. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering.
Exact Sciences 2015 J.P Morgan Healthcare Conference PresentationExact Sciences
Exact Sciences CEO Kevin Conroy delivers an update on the commercial launch of Cologuard and tells the Exact Sciences story at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco California. The presentation took place January 14, 2015.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Aridis Pharmaceuticals is a late-stage clinical development company, leading the creation of transformative, first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. The company’s lead drug candidate for acute pneumonia met all endpoints for its phase 2 clinical trial and the Company is now preparing for a phase 3 study. Its pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of viral pandemics and antimicrobial resistant (AMR) bacteria. Its anti-toxin monoclonal antibody approach is a proven Mechanism of Action and has shown efficacy as a combination therapy in reducing acute pneumonia patients time in ICU as compared to the current standard of care, which is antibiotics. In addition to its phase 3 program, ARDS also has a phase 2 asset for the treatment of Bacteria HAP/VAP LPS 011. It also recently began enrolling for a phase 2 clinical trial for the treatment of Cystic Fibrosis patients with acute pneumonia, a program funded by the Cystic Fibrosis Foundation for $7.5 million. Importantly, ARDS is also preparing to launch a Phase 1/2 clinical trial in the second half of 2021 with its novel inhalation antibody technology for emerging COVID-19 mutated variants. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering.
Exact Sciences 2015 J.P Morgan Healthcare Conference PresentationExact Sciences
Exact Sciences CEO Kevin Conroy delivers an update on the commercial launch of Cologuard and tells the Exact Sciences story at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco California. The presentation took place January 14, 2015.
Exact Sciences Corp. announced that the company continued its strong performance during the third quarter ended Sept. 30, 2015, completing 34,000 Cologuard tests, an increase of 60 percent from the second quarter, which resulted in $12.6 million in revenues. The cumulative number of ordering physicians grew to 21,000 during the quarter, an increase of 42 percent.
Details on Exact Sciences' Lung Cancer Partnership With MD AndersonExact Sciences
Exact Sciences will partner with MD Anderson to jointly develop and commercialize blood-based screening and diagnostics tests for the early detection of lung cancer. More details herein.
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
Improving profitability for small businessBen Wann
In this comprehensive presentation, we will explore strategies and practical tips for enhancing profitability in small businesses. Tailored to meet the unique challenges faced by small enterprises, this session covers various aspects that directly impact the bottom line. Attendees will learn how to optimize operational efficiency, manage expenses, and increase revenue through innovative marketing and customer engagement techniques.
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
Cracking the Workplace Discipline Code Main.pptxWorkforce Group
Cultivating and maintaining discipline within teams is a critical differentiator for successful organisations.
Forward-thinking leaders and business managers understand the impact that discipline has on organisational success. A disciplined workforce operates with clarity, focus, and a shared understanding of expectations, ultimately driving better results, optimising productivity, and facilitating seamless collaboration.
Although discipline is not a one-size-fits-all approach, it can help create a work environment that encourages personal growth and accountability rather than solely relying on punitive measures.
In this deck, you will learn the significance of workplace discipline for organisational success. You’ll also learn
• Four (4) workplace discipline methods you should consider
• The best and most practical approach to implementing workplace discipline.
• Three (3) key tips to maintain a disciplined workplace.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
1. Diagnostics for the early detection
and prevention of colon cancer
Cowen and Company
35th Annual Health Care Conference
March 3, 2015
2. Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended
to be covered by the "safe harbor" created by those sections. Forward-looking statements can generally be identified by the use of
forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate"
or other comparable terms. All statements other than statements of historical facts included in this presentation regarding our
strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of
forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated
results of our sales and marketing efforts, expectations concerning payor reimbursement and the anticipated results of our product
development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they
are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking
statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to
predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those
indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important
factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking
statements include, among others, the following: our ability to successfully and profitably market our products; the acceptance of
our products by patients and health care providers; the amount and nature of competition from other cancer screening products
and procedures; our ability to maintain regulatory approvals and comply with applicable regulations; our success establishing and
maintaining collaborative and licensing arrangements; our ability to successfully develop new products; and the other risks and
uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of
Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form
10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made
from time to time, whether as a result of new information, future developments or otherwise.
Safe Harbor Statement
1
3. OUR FIRST MISSION
To partner with healthcare providers,
payers, patients and advocacy
groups to help eradicate colorectal
cancer
2
8. 136,830
Source: ACS Cancer Facts & Figures 2014; all figures annual
Ovary Prostate Pancreas Breast LungCervix
14,270
29,480
39,590
40,430
50,310
159,260
4,020
Annual U.S. cancer mortality
Colorectal cancer: America’s second-leading cancer killer
new U.S. cases
Colorectal
7
9. Source: J Natl Cancer Inst. 2009; 101:1225-1227 (Itzkowitz)
– Journal of the National Cancer Institute
Major opportunity to improve colorectal cancer screening
The most preventable, yet
least prevented cancer.
8
10. Detection and removal of polyps prevents cancer
Pre-cancerous polyp
Stages of colon cancer
10-15
years
9
Sources: N Engl J Med 2012;366:687-96 (Zauber);
Gastro 1997;112:594-692 (Winawer)
11. Detecting colorectal cancer early is important
9out of 10
Survive 5 years if
Diagnosed in Stages I or II
1out of 10
Survive 5 years if
Diagnosed in Stage IV
10 Source: SEER 18 2004-2010
12. Rising cost of colorectal cancer treatment
11
2010 2015 2020
Projected
annual
treatment costs
in 2020
$20B
$14B
Source: J Natl Cancer Inst. 2011; 103:1-12 (Mariotto)
13. American Cancer Society goal: 80% by 2018
Colorectal
Cervical
U.S. Cancer Screening Rates
83%
65%
12 Source: ACS Cancer Prevention & Early Detection Facts & Figures 2013; Company
estimates
14m
more
screened
15. A powerful value proposition to physicians & patients
①Cologuard is patient friendly
②Cologuard is safe and effective
③Engagement drives patient
compliance
14
16. 15 Source: N Engl J Med 2014;370:1287-97. DOI: 10.1056/NEJMoa1311194 (Imperiale)
17. Cologuard in practice guidelines
*Guidelines based on a previous stool DNA test developed by Exact Sciences
Update
American Cancer Society
American College of Gastroenterology*
2014
U.S. Preventive Services Task Force
2009
Expected
2015
Guideline
Under the Affordable Care Act, if USPSTF issues A/B rating
then all commercial payers must cover Cologuard
16
18. 17
Sales & marketing strategy
PHYSICIANS
140+ person sales team
Med journal ads
Hyper-targeted digital
Direct mail/email
PATIENTS
Big-stage print
Targeted digital
Social media
Search
PAYERS
CMS reimbursement
Managed care team
Compelling cost-
effectiveness data
19. 6% of PCPs have been visited at least
once by a sales rep (~16,000)
Reach of Current Sales Force
6%
Not visited Visited
18
~280,000 Primary
Care Providers
20. Expanding the Sales Force
19
~80 reps
Oct 2014 By end of 2015
~200 reps
19
Mar 2015
~140 reps
22. Key Fourth-Quarter 2014 Cologuard Metrics
21
① 4,000+ ordering physicians
② 4,000+ test results reported
③ 75% patient compliance rate
(The number of valid test results reported divided by the number of collection kits
shipped to patients 60 or more days prior to Dec. 31, 2014)
④ $1.5 million in revenue
24. First-Quarter Cologuard Launch Progress
23
Total ordering physicians >6,300
First-quarter valid test results >5,200
− 4,000 completed in Q4
Data as of 2/20/15
25. 31%
75%
28%
16%
Completed with no
compliance call
Completed after 1
compliance call
Completed after 2
compliance calls
Overall Compliance
Rate
Active Engagement Doubles Participation
Fourth-Quarter 2014
24
Compliance
doubled
Two+
calls
One
call
+
26. Cologuard’s Positive Effect on Compliance
Never
Screened or
DRE Only
39%
10%
Colonoscopy
51%
FIT/FOBT
Only
25
Source: Internal patient survey
Data as of December 31, 2014
49% never had
a colonoscopy
27. Factors for Cologuard Success 2015 and Beyond
① Expanding reach and frequency with providers
② Expanding medical education programs
• Peer-to-peer physician outreach
③ Private payor coverage and reimbursement
④ USPSTF guideline inclusion
• HEDIS quality measures
• ACA insurance coverage mandate
26
28. European launch of Cologuard
27
• Large, addressable market
• High colon cancer rate
(152K deaths annually)
• Low screening rates ~20%
• 136M people 50-75 years old
• CE mark received
December 2014
• Core team in place
• Initial targets: UK, Germany,
Austria, Switzerland & Italy
29. Exclusive Mayo Clinic collaboration on
early detection of GI cancers
28
Colorectal
Esophageal
Pancreatic
• Expand indication of Cologuard
• High risk (e.g. family history, IBD)
• 40-50 years old (long term)
• Diagnosis of Barrett’s esophagus
(a high-risk condition for cancer)
• Early detection of esophageal cancer
• Diagnose pancreatic cancer earlier
and with greater accuracy
30. Financials and key milestones
• $1.5 million in revenue during Q4 2014
• Cash balance of $282.8 million as of December 31, 2014
• $100-million offering closed in December 2014
• > 6,300 ordering physicians since FDA approval
29